Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial-Reference-Cited by-同舟云学术

Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial

Published:2013-02 Issue:2 Volume:14 Page:125-133
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Lang Istvan,Brodowicz Thomas,Ryvo Larisa,Kahan Zsuzsanna,Greil Richard,Beslija Semir,Stemmer Salomon M,Kaufman Bella,Zvirbule Zanete,Steger Günther G,Melichar Bohuslav,Pienkowski Tadeusz,Sirbu Daniela,Messinger Diethelm,Zielinski Christoph

Publisher

Elsevier BV

Subject

Oncology

Reference21 articles.

1. 1st International consensus guidelines for advanced breast cancer (ABC 1);Cardoso;Breast,2012

2. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Cardoso;Ann Oncol,2011

3. Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer;Gray;J Clin Oncol,2009

4. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer;Miles;J Clin Oncol,2010

5. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative locally recurrent or metastatic breast cancer;Robert;J Clin Oncol,2011

Cited by 82 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Racial and Ethnic Disparities in European Breast Cancer Clinical Trials;Cancers;2024-04-29

2. Ambulatory Routine Care in Oncology in Germany: Real-World Survival Data;Oncology Research and Treatment;2024

3. The Combined Therapeutic Effect of Capecitabine and Naringin on HER2+ (SK-BR-3) and HER2- (MCF-7) Human Breast Cancer Cells Lines;2023-05-09

4. Efficacy Evaluation of Bevacizumab Combined with Capecitabine in the Treatment of HER2-Negative Metastatic Breast Cancer: A Meta-Analysis;Journal of Oncology;2023-02-08

5. Pre-Clinical and Clinical Evidence of Recent Therapeutic Trends and Spotting Possibility of Cure in Near Future;Therapeutic Drug Targets and Phytomedicine For Triple Negative Breast Cancer;2023-01